VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
ENOVEnovis Corporation
$21.97$1.3B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

ENOV logoEnovis Corporation(ENOV)Earnings, Financials & Key Ratios

ENOV•NYSE
Price updated Jun 19, 2026
SectorIndustrialsIndustryIndustrial MachinerySub-IndustryPrecision instruments and test equipment
AboutEnovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.Show more
  • Revenue$2.25B+6.7%
  • EBITDA$276M+156.1%
  • Net Income-$1.18B-43.5%
  • EPS (Diluted)-20.86-39.7%
  • Gross Margin59.84%+6.8%
  • EBITDA Margin12.26%+152.6%
  • Operating Margin-0.84%+97.7%
  • Net Margin-52.69%-34.5%
  • ROE-58.4%-111.7%

ENOV Key Insights

Enovis Corporation (ENOV) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Strong 5Y sales CAGR of 14.9%
  • ✓Trading at only 0.8x book value

✗Weaknesses

  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when ENOV posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ENOV Price & Volume

Enovis Corporation (ENOV) stock price & volume — 10-year historical chart

Loading chart...

ENOV Growth Metrics

Enovis Corporation (ENOV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-5.52%
5 Years14.94%
3 Years12.88%
TTM5.96%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-40.49%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-43.51%

Return on Capital

10 Years-1.14%
5 Years-4.59%
3 Years-6.94%
Last Year-0.51%

ENOV Recent Earnings

Enovis Corporation (ENOV) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 7, 2026
Metric
Actual
Est
EPS
$0.89+8.5%
$0.82
Rev
$589M+3.0%
$572M
Q1 2026
Feb 26, 2026
Metric
Actual
Est
EPS
$0.95+17.3%
$0.81
Rev
$576M-1.2%
$583M
Q4 2025
Nov 6, 2025
Metric
Actual
Est
EPS
$0.75+11.9%
$0.67
Rev
$549M-6.1%
$584M
Q3 2025
Aug 7, 2025
Metric
Actual
Est
EPS
$0.79+6.8%
$0.74
Rev
$565M+4.8%
$539M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 7, 2026
$0.89vs $0.82+8.5%
$589Mvs $572M+3.0%
Q1 2026Feb 26, 2026
$0.95vs $0.81+17.3%
$576Mvs $583M-1.2%
Q4 2025Nov 6, 2025
$0.75vs $0.67+11.9%
$549Mvs $584M-6.1%
Q3 2025Aug 7, 2025
$0.79vs $0.74+6.8%
$565Mvs $539M+4.8%
Based on last 12 quarters of dataView full earnings history →

ENOV Peer Comparison

Enovis Corporation (ENOV) competitors in Precision instruments and test equipment — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
HOLX logoHOLXHologic, Inc.Direct Competitor16.97B76.0130.531.74%13.18%11.01%0.52
NVCR logoNVCRNovoCure LimitedDirect Competitor1.62B14.28-11.708.28%-25.66%-50.82%0.85
INVA logoINVAInnoviva, Inc.Direct Competitor1.66B22.496.8218.52%118.91%47.59%0.23
LMAT logoLMATLeMaitre Vascular, Inc.Direct Competitor2.14B93.9537.2813.53%24.35%16.19%0.47
ATRC logoATRCAtriCure, Inc.Direct Competitor1.46B28.80-12014.88%-0.83%-0.95%0.18
ZBH logoZBHZimmer Biomet Holdings, Inc.Product Competitor17.22B87.9724.787.2%9.05%5.77%0.59
SNN logoSNNSmith & Nephew plcProduct Competitor12.77B30.0820.896.34%6.88%15.06%0.63
GMED logoGMEDGlobus Medical, Inc.Product Competitor10.69B79.2320.2116.65%18.92%13.04%0.03

Compare ENOV vs Peers

Enovis Corporation (ENOV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs HOLX

Most directly comparable listed peer for ENOV.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare ENOV against a more recognizable public peer.

Peer Set

Compare Top 5

vs HOLX, NVCR, INVA, LMAT

ENOV Income Statement

Enovis Corporation (ENOV) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
3.3B3.67B3.33B1.12B1.43B1.56B1.71B2.11B2.25B2.28B
Revenue Growth %
-9.51%11.11%-9.25%-66.32%27.26%9.6%9.22%23.46%6.66%5.96%
Cost of Goods Sold
2.27B2.53B1.93B517.06M648.51M693.72M716.42M926.87M902.79M983.94M
COGS % of Revenue
68.81%69.11%57.89%46.14%45.47%44.38%41.96%43.98%40.16%-
Gross Profit
1.03B▲ 0%
1.13B▲ 10.0%
1.4B▲ 23.7%
603.64M▼ 56.9%
777.67M▲ 28.8%
869.38M▲ 11.8%
990.78M▲ 14.0%
1.18B▲ 19.2%
1.35B▲ 13.9%
1.29B▲ 0%
Gross Margin %
31.19%30.89%42.11%53.86%54.53%55.62%58.04%56.02%59.84%56.81%
Gross Profit Growth %
-10.14%10.04%23.68%-56.92%28.83%11.79%13.96%19.17%13.93%-
Operating Expenses
732.34M818.21M1.2B669.82M840.47M940.56M1.06B1.96B1.36B1.23B
OpEx % of Revenue
22.19%22.31%35.99%59.77%58.93%60.17%61.88%92.83%60.68%-
Selling, General & Admin
732.34M818.21M1.13B515.47M665.77M772.91M830.3M939.36M1.07B1.06B
SG&A % of Revenue
22.19%22.31%34.02%46%46.68%49.45%48.64%44.57%47.6%-
Research & Development
42.9M34.2M034.27M49.09M60.83M75.33M91.3M120.33M123.34M
R&D % of Revenue
1.3%0.93%-3.06%3.44%3.89%4.41%4.33%5.35%-
Other Operating Expenses
-46.93M39K65.3M120.09M125.61M106.82M150.85M925.81M173.65M365K
Operating Income
29.15M▲ 0%
236.94M▲ 712.8%
203.61M▼ 14.1%
-66.18M▼ 132.5%
-62.8M▲ 5.1%
-71.18M▼ 13.3%
-65.71M▲ 7.7%
-775.72M▼ 1080.5%
-18.87M▲ 97.6%
61.48M▲ 0%
Operating Margin %
0.88%6.46%6.12%-5.91%-4.4%-4.55%-3.85%-36.81%-0.84%2.7%
Operating Income Growth %
-87.75%712.81%-14.07%-132.5%5.11%-13.34%7.68%-1080.54%97.57%-
EBITDA
152.57M378.82M439.64M180.05M200.12M148.53M151.4M-490.92M275.51M357.78M
EBITDA Margin %
4.62%10.33%13.21%16.07%14.03%9.5%8.87%-23.29%12.26%15.7%
EBITDA Growth %
-56.14%148.29%16.05%-59.05%11.15%-25.78%1.93%-424.26%156.12%171.44%
D&A (Non-Cash Add-back)
123.42M141.88M236.03M246.23M262.92M219.71M217.11M284.8M294.38M296.3M
EBIT
36.99M141.45M170M-66.18M-92.67M21.98M-47.38M-765.82M-1.12B-489.08M
Net Interest Income
-40.11M-49.08M-119.5M-52.82M-29.11M-24.75M-19.75M-57.1M-34.82M-34.8M
Interest Income
00000200K00022M
Interest Expense
40.11M49.08M119.5M52.82M29.11M24.95M19.75M57.1M34.82M56.8M
Other Income/Expense
-147.58M-59.17M-153.12M-52.82M-58.98M69.11M-1.42M-47.2M-1.14B-1.16B
Pretax Income
-11.99M▲ 0%
182.8M▲ 1625.1%
50.49M▼ 72.4%
-119.01M▼ 335.7%
-121.78M▼ 2.3%
-2.07M▲ 98.3%
-67.13M▼ 3144.5%
-822.92M▼ 1125.9%
-1.16B▼ 40.9%
-1.1B▲ 0%
Pretax Margin %
-0.36%4.99%1.52%-10.62%-8.54%-0.13%-3.93%-39.05%-51.57%-48.34%
Income Tax
42.55M-21K31.63M-44.58M-19.53M36.12M-13.29M4.49M22.29M33.11M
Effective Tax Rate %
-355.03%-0.01%62.64%37.46%16.04%-1745.77%19.8%-0.55%-1.92%-3.01%
Net Income
151.09M▲ 0%
140.2M▼ 7.2%
-527.65M▼ 476.4%
42.63M▲ 108.1%
71.66M▲ 68.1%
-13.29M▼ 118.5%
-33.26M▼ 150.2%
-825.49M▼ 2381.9%
-1.18B▼ 43.5%
-1.14B▲ 0%
Net Margin %
4.58%3.82%-15.86%3.8%5.02%-0.85%-1.95%-39.17%-52.69%-49.91%
Net Income Growth %
17.94%-7.21%-476.36%108.08%68.11%-118.55%-150.23%-2381.87%-43.48%-40.49%
Net Income (Continuing)
46.08M121.87M18.86M-74.43M-102.25M-38.19M-53.84M-827.42M-1.18B-1.13B
Discontinued Operations
123.43M32.6M-536.01M120.2M178.53M26.43M21.11M2.6M-1.91M-1.17M
Minority Interest
226.85M207.19M48.2M44.49M44.05M1.72M2.31M2.07M2.26M2.57M
EPS (Diluted)
3.66▲ 0%
3.48▼ 4.9%
0.41▼ 88.2%
1.11▲ 170.7%
-2.02▼ 282.0%
-0.28▲ 86.1%
-0.61▼ 117.9%
-14.93▼ 2347.5%
-20.86▼ 39.7%
-20.02▲ 0%
EPS Growth %
17.31%-4.92%-88.22%170.73%-281.98%86.14%-117.86%-2347.54%-39.72%-43.51%
EPS (Basic)
3.693.500.421.13-2.02-0.28-0.61-14.93-20.86-
Diluted Shares Outstanding
41.33M40.29M45.56M46.3M51.14M54.07M54.49M55.28M56.79M56.79M
Basic Shares Outstanding
40.95M40.1M45.24M45.59M51.14M54.07M54.53M55.28M56.79M56.79M
Dividend Payout Ratio
----------

ENOV Balance Sheet

Enovis Corporation (ENOV) balance sheet — assets, liabilities & shareholders' equity

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
2.07B1.96B1.4B1.36B2.3B795.02M896.52M1.15B1.21B1.24B
Cash & Short-Term Investments
411.63M245.02M109.63M101.07M680.25M24.3M36.19M48.17M36.39M33.13M
Cash Only
262.02M245.02M109.63M101.07M680.25M24.3M36.19M48.17M36.39M33.13M
Short-Term Investments
149.61M000000000
Accounts Receivable
970.2M386.59M561.87M517.01M254.96M267.38M291.48M407.03M442.79M444.21M
Days Sales Outstanding
107.338.4861.63168.3865.2562.4462.3270.4971.8970.99
Inventory
429.63M496.54M571.56M564.82M356.23M426.64M468.83M547.12M584.38M602.54M
Days Inventory Outstanding
69.0671.52108.29398.72200.5224.48238.86215.46236.27225.25
Other Current Assets
258.38M1.14B90.76M113.42M985.79M48.16M71.11M107.88M101.22M110.29M
Total Non-Current Assets
4.65B4.65B5.98B5.99B6.21B3.48B3.61B3.57B2.63B2.59B
Property, Plant & Equipment
552.8M503.34M664.56M660.9M311.6M303.62M334.3M473.42M579.32M594.22M
Fixed Asset Turnover
5.97x7.28x5.01x1.70x4.58x5.15x5.11x4.45x3.88x4.04x
Goodwill
2.54B2.58B3.2B3.31B1.93B1.98B2.06B1.69B718.3M711.9M
Intangible Assets
1.02B1.01B1.72B1.66B1.15B1.11B1.13B1.32B1.24B1.19B
Long-Term Investments
73.49M62.52M41.63M31.82M15.42M16.5M020.4M21.4M21.4M
Other Non-Current Assets
543.27M552.56M396.49M350.83M2.8B80.29M90.25M68.38M71.95M93.96M
Total Assets
6.72B▲ 0%
6.6B▼ 1.8%
7.39B▲ 11.9%
7.35B▼ 0.5%
8.52B▲ 15.8%
4.27B▼ 49.8%
4.51B▲ 5.5%
4.72B▲ 4.6%
3.83B▼ 18.7%
3.83B▲ 0%
Asset Turnover
0.49x0.56x0.45x0.15x0.17x0.37x0.38x0.45x0.59x0.53x
Asset Growth %
5.26%-1.75%11.86%-0.48%15.84%-49.82%5.52%4.64%-18.73%-67.98%
Total Current Liabilities
1.1B1.2B857.31M811.66M1.02B565.2M369.61M529M598.47M608.66M
Accounts Payable
587.13M291.23M359.78M330.25M155.21M135.63M132.47M179.1M187.53M213.62M
Days Payables Outstanding
94.3841.9568.17233.1387.3671.3667.4970.5375.8275.3
Short-Term Debt
5.77M5.02M67.66M66.77M29.64M243.56M21.57M20.03M59.74M60.23M
Deferred Revenue (Current)
145.85M16.83M16.01M36.74M9.2M3.56M2.95M6.23M6.5M23.41M
Other Current Liabilities
206.56M758.5M258.31M222.16M736.57M101.72M114.21M188.97M212.42M191.31M
Current Ratio
1.89x1.63x1.64x1.68x2.25x1.41x2.43x2.17x2.02x2.04x
Quick Ratio
1.49x1.22x0.97x0.98x1.90x0.65x1.16x1.13x1.04x1.05x
Cash Conversion Cycle
81.9968.05101.76333.97178.39215.55233.69215.42232.34220.94
Total Non-Current Liabilities
1.9B1.93B3.04B2.95B2.83B258.25M719.03M1.63B1.74B1.74B
Long-Term Debt
1.06B1.19B2.28B2.2B2.08B40M466.16M1.31B1.26B1.29B
Capital Lease Obligations
00136.4M139.23M56.55M51.26M48.68M52.46M58M223.22M
Deferred Tax Liabilities
00000000102.7M102.7M
Other Non-Current Liabilities
829.75M747.26M619.31M608.62M695.72M166.99M204.18M263.52M321.87M393.81M
Total Liabilities
2.99B3.13B3.9B3.76B3.85B823.45M1.09B2.15B2.34B2.35B
Total Debt
1.06B1.2B2.49B2.41B2.16B334.82M536.42M1.4B1.38B1.41B
Net Debt
799.05M1.12B2.38B2.31B1.48B310.52M500.23M1.36B1.34B1.38B
Debt / Equity
0.28x0.34x0.71x0.67x0.46x0.10x0.16x0.55x0.92x0.95x
Debt / EBITDA
6.95x3.16x5.66x13.39x10.82x2.25x3.54x-5.01x3.94x
Net Debt / EBITDA
5.24x2.96x5.41x12.82x7.42x2.09x3.30x-4.88x3.85x
Interest Coverage
0.92x2.88x1.42x-1.25x-3.18x0.88x-2.40x-13.41x-32.29x-8.61x
Total Equity
3.73B▲ 0%
3.48B▼ 6.7%
3.49B▲ 0.4%
3.59B▲ 2.8%
4.66B▲ 29.9%
3.45B▼ 26.0%
3.42B▼ 0.8%
2.56B▼ 25.0%
1.49B▼ 41.8%
1.48B▲ 0%
Equity Growth %
20.49%-6.72%0.36%2.82%29.92%-25.99%-0.84%-25.04%-41.82%-146.17%
Book Value per Share
90.1886.3176.6077.4991.1563.8162.7746.3926.2726.05
Total Shareholders' Equity
3.5B3.27B3.44B3.54B4.62B3.45B3.42B2.56B1.49B1.48B
Common Stock
123K117K118K118K52K54K55K56K57K58K
Retained Earnings
846.49M991.84M479.56M517.37M589.02M575.73M542.47M-283.02M-1.47B-1.48B
Treasury Stock
0000000000
Accumulated OCI
-574.37M-780.18M-483.85M-452.11M-516.01M-53.43M-24.88M-127.89M-91.36M-103.76M
Minority Interest
226.85M207.19M48.2M44.49M44.05M1.72M2.31M2.07M2.26M2.57M

ENOV Cash Flow Statement

Enovis Corporation (ENOV) cash flow — operating, investing & free cash flow history

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
218.77M226.37M130.95M301.94M356.1M-55.86M134.99M113.5M217.29M242.84M
Operating CF Margin %
6.63%6.17%3.94%26.94%24.97%-3.57%7.91%5.39%9.67%-
Operating CF Growth %
-11.42%3.47%-42.15%130.58%17.94%-115.69%341.65%-15.92%91.44%2169.67%
Net Income
169.51M154.47M-517.15M45.77M76.28M-11.76M-33.26M-824.82M-1.18B-1.14B
Depreciation & Amortization
134.75M141.88M236.03M246.23M262.92M219.71M217.1M284.8M294.38M297.05M
Stock-Based Compensation
21.55M25.1M21.96M28.91M35.35M38.95M34.06M29.66M32.92M26.26M
Deferred Taxes
12.07M-66.57M-590K-29.22M-22.19M6.32M-27.41M-10.02M-2.23M-19.65M
Other Non-Cash Items
-86.98M4.82M522.15M5.25M20.84M-88.59M-28.24M647.81M1.06B1.03B
Working Capital Changes
-32.13M-33.33M-131.46M4.99M-17.1M-220.49M-27.27M-13.93M15.46M27.33M
Change in Receivables
-44.34M-72.41M49.92M42.69M-110.98M-45.19M-16.32M-57.05M-10.75M878K
Change in Inventory
-34.02M-47.16M-44.89M23.79M-129.97M-118.79M-24.74M39.07M-11.98M-10.76M
Change in Payables
10.27M70.08M-119.33M-30.75M178.47M-11.84M-6.64M13.98M-1.14M21.56M
Cash from Investing
89.88M-167.85M-1.63B-175.08M-320.48M-176.39M-242.47M-955.47M-179.37M-171.95M
Capital Expenditures
-68.77M-69.65M-125.4M-114.78M-104.24M-105.45M-122.22M-180.71M-197.38M-200.37M
CapEx % of Revenue
2.08%1.9%3.77%10.24%7.31%6.75%7.16%8.57%8.78%8.79%
Acquisitions
143.54M-272.51M-1.52B-69.85M-223.27M-73.68M-152.81M-769.91M16.4M-21.8M
Investments
----------
Other Investing
15.1M34.83M7.78M9.55M7.03M2.75M32.57M-4.84M1.6M50.22M
Cash from Financing
-280.45M-47.15M1.37B-131.65M584.91M-465.13M127.8M846.82M-52.4M-77.57M
Debt Issued (Net)
-277.38M158.24M1.11B-118.32M-150.41M-1.59B217.19M859.23M-43.6M-72.43M
Equity Issued (Net)
6.94M-200M11.88M3.5M745.18M5.81M1.78M-2.9M1.32M1.6M
Dividends Paid
0000000000
Share Repurchases
0-200M00000-4.77M00
Other Financing
-10.01M-5.39M248.83M-16.84M-9.87M1.12B-91.17M-9.51M-10.12M-6.75M
Net Change in Cash
40.29M▲ 0%
-17M▼ 142.2%
-135.39M▼ 696.4%
-8.56M▲ 93.7%
618.3M▲ 7320.6%
-695.08M▼ 212.4%
20.54M▲ 103.0%
3.33M▼ 83.8%
-11.78M▼ 453.2%
-5.33M▲ 0%
Free Cash Flow
150M▲ 0%
156.72M▲ 4.5%
5.55M▼ 96.5%
187.15M▲ 3274.5%
251.86M▲ 34.6%
-161.31M▼ 164.0%
12.77M▲ 107.9%
-67.21M▼ 626.5%
19.92M▲ 129.6%
35.92M▲ 0%
FCF Margin %
4.55%4.27%0.17%16.7%17.66%-10.32%0.75%-3.19%0.89%1.58%
FCF Growth %
-18.35%4.48%-96.46%3274.5%34.58%-164.05%107.91%-626.52%129.63%192.15%
FCF per Share
3.633.890.124.044.92-2.980.23-1.220.350.63
FCF Conversion (FCF/Net Income)
1.45x1.61x-0.25x7.08x4.97x4.20x-4.06x-0.14x-0.18x-0.03x
Interest Paid
43.5M50.39M139.27M104.62M85.49M37.09M16.33M51.83M00
Taxes Paid
70.67M97.45M134.91M59.38M47.19M31.36M12.52M10.8M00

ENOV Key Ratios

Enovis Corporation (ENOV) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)
4.43%3.89%-15.15%1.2%1.74%-0.33%-0.97%-27.59%-58.4%-60.04%
Return on Invested Capital (ROIC)
0.5%3.97%2.97%-0.84%-0.78%-1.08%-1.28%-14.84%-0.42%1.41%
Gross Margin
31.19%30.89%42.11%53.86%54.53%55.62%58.04%56.02%59.84%56.81%
Net Margin
4.58%3.82%-15.86%3.8%5.02%-0.85%-1.95%-39.17%-52.69%-49.91%
Debt / Equity
0.28x0.34x0.71x0.67x0.46x0.10x0.16x0.55x0.92x0.95x
Interest Coverage
0.92x2.88x1.42x-1.25x-3.18x0.88x-2.40x-13.41x-32.29x-8.61x
FCF Conversion
1.45x1.61x-0.25x7.08x4.97x4.20x-4.06x-0.14x-0.18x-0.03x
Revenue Growth
-9.51%11.11%-9.25%-66.32%27.26%9.6%9.22%23.46%6.66%5.96%
Related:ENOV Dividend History·ENOV Revenue History·ENOV Price History·ENOV P/E History·ENOV Financial Ratios·ENOV Institutional Holders

ENOV SEC Filings & Documents

Enovis Corporation (ENOV) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 7, 2026·SEC

Material company update

Feb 26, 2026·SEC

Material company update

Jan 12, 2026·SEC

10-K Annual Reports

2
FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 26, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

May 7, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 7, 2025·SEC

ENOV Frequently Asked Questions

Enovis Corporation (ENOV) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Enovis Corporation (ENOV) reported $2.28B in revenue for fiscal year 2025. This represents a 559% increase from $345.5M in 2005.

Enovis Corporation (ENOV) grew revenue by 6.7% over the past year. This is steady growth.

Enovis Corporation (ENOV) reported a net loss of $1.14B for fiscal year 2025.

Dividend & Returns

Enovis Corporation (ENOV) has a return on equity (ROE) of -58.4%. Negative ROE indicates the company is unprofitable.

Enovis Corporation (ENOV) generated $35.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in ENOV back in 2005?

Total return calculator · dividends reinvested · 21+ years of data

See returns →

How much would $100/month in ENOV be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →